As a tiny vesicle with a lipid bilayer membrane that can be secreted by most cells in the body, extracellular vesicles or exosomes carry and transmit important signal molecules, Therefore, they have been a research hotspot in biomedicine and biomaterials due to their size advantages and huge potential in drug therapy.
With a comprehensive intellectual property portfolio creation including proprietary manufacturing, purification, and preservation methods, as well as a clinical translation platform establishment, our EV novel therapeutics, Troy-Car-Exos, are engineered exosomes with safe and potent modality for precision delivery of advanced payloads. Troy-Car-Exos owned patented endogenous immune checkpoint antibody and designed a novel genetic engineering modification method to fuse on the EV's membrane proteins. Furthermore, they are loaded with small molecules and nucleic acid drugs with high efficiency. This nano-level immune checkpoint nanobody as the target of Troy-Car-Exos, is highly-expressed outside the double-layer phospholipid layer of exosomes, which increases the specificity of exosomes to attack tumors instead of normal tissue cells. In addition, Troy-Car-Exos with immune checkpoint nanobodies can also prohibit the inhibitory effect of immune cells caused by immune checkpoint antigens after binding to tumor cells, thus increasing the killing of tumor cells by T cells.
Interesting Elements:
Troy-Car-Exos are loaded with nucleic acid and chemotherapy drug. The function of nucleic acid drug is to prevent distant metastasis, while chemotherapy drug can kill tumor cells. Combining the above two functions, Troy-Car-Exos can effectively kill tumors and inhibit the distant metastasis at the same time.